Trials / Recruiting
RecruitingNCT06458595
Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
A Phase I/II Study to Evaluate the Tolerability, Safety and Efficacy of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD).
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KH658 | KH658 Ophthalmic Injection |
Timeline
- Start date
- 2024-06-28
- Primary completion
- 2026-03-31
- Completion
- 2026-12-28
- First posted
- 2024-06-13
- Last updated
- 2024-11-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06458595. Inclusion in this directory is not an endorsement.